Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HS-10370 combination therapy versus tislelizumab plus platinum doublet chemotherapy as first-line treatment for KRAS G12C-mutant advanced non-squamous non-small cell lung cancer
CTR20263544Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hs-10370 in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Sep 2026; status: active.
02
Drugs
hs-10370
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263544.